Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.

European journal of human genetics : EJHG - 1 May 2008

Smith Jennifer A, Arnett Donna K, Kelly Reagan J, Ordovas Jose M, Sun Yan V, Hopkins Paul N, Hixson James E, Straka Robert J, Peacock James M, Kardia Sharon L R

Abstract excerpt

Metabolic response to the triglyceride (TG)-lowering drug, fenofibrate, is shaped by interactions between genetic and environmental factors, yet knowledge regarding the genetic determinants of this response is primarily limited to single-gene effects. Since very low-density lipoprotein (VLDL) is the central carrier of fasting TG, identifying factors that affect both total TG and VLDL-TG response to fenofibrate is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fasting
Share to Hypolipidemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipid Metabolism

Share to Lipoproteins, VLDL

Share to Polymorphism, Single Nucleotide

Share to Reproducibility of Results

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 18212815
DOI: 10.1038/sj.ejhg.5202003
PMCID: PMC2546577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.PMID 18212815Read ↗

Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.Semantic proximity Read ↗

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.Semantic proximity Read ↗

A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.Semantic proximity Read ↗

Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.Semantic proximity Read ↗

Uncovering the complex genetic architecture of human plasma lipidome using machine learning methods.Semantic proximity Read ↗

Identifying gene-gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts.Semantic proximity Read ↗

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.Semantic proximity Read ↗

Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.Semantic proximity Read ↗

Genetic determinants of plasma triglycerides.Semantic proximity Read ↗

Pharmacogenomics of blood lipid regulation.Semantic proximity Read ↗

Pharmacogenetics of lipid diseases.Semantic proximity Read ↗

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.